News Data sets up phase 3 trials for Novo's amycretin in diabetes Novo Nordisk has decided to move its amycretin into pivotal trials in type 2 diabetes after a phase 2 readout.
News Disappointment as Novo's oral GLP-1 fails in Alzheimer's GLP-1 agonists have been shown to be beneficial in a lengthening list of diseases, but it seems Alzheimer's disease may not be among them.
News Stroke data breathes life back into Bayer's asundexian Prospects for Bayer's oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.
News J&J abandons Alzheimer's antibody in setback for tau Hopes that anti-tau drugs could emerge as treatments for Alzheimer's have been dented by the failure of a phase 2b trial of J&J's posdinemab.
News Neuralink rival Paradromics cleared to start speech trial Brain computer interface developer Paradromics has been cleared to start a US clinical trial of its Connexus implant for speech restoration.
News Agios shares slump on sickle cell disease data Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.
News FDA follows experts' advice and blocks Capricor DMD therapy The FDA has dashed Capricor's hope of getting approval for its cell therapy for Duchenne muscular dystrophy, wreaking havoc with its share price.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.